Navigation Links
Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO/ESMO on September 22, 2009
Date:9/17/2009

pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. Micromet's collaboration partners include Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of Micromet's BiTE antibody MT110, which targets the epithelial cell adhesion molecule (EpCAM), currently in a phase 1 clinical trial for the treatment of patients with solid tumors, and other product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon fur
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Fla. , July 30, 2014  Dyadic ... biotechnology company whose patented and proprietary technologies are ... and other proteins for the bioenergy, bio-based chemical, ... appointment of Thomas "Tom" Dubinski as Vice President ... for leading the financial and information technology operations ...
(Date:7/30/2014)... 30, 2014 NCERC at Southern ... present his findings on corn stover pretreatment methods ... week in Washington, D.C. , “Arun’s selection ... is a testament to the success of our ... “Thanks to the foresight and vision of SIUE ...
(Date:7/30/2014)... LayerBio, Inc., an MIT spinoff developing novel drug ... seed financing from friends and family investors. Proceeds from ... novel sustained-release product for ophthalmology. , "We are grateful ... to this important work," said Dr. Ken Mandell, Founder ... areas in which innovations in drug delivery have already ...
(Date:7/29/2014)... --  Sequenom, Inc. (NASDAQ: SQNM ), ... solutions, and Mayo Medical Laboratories (MML), the ... the United States , have announced a license ... "We have great appreciation for Mayo Clinic,s commitment ... the opportunity to partner with the organization,s leading clinical ...
Breaking Biology Technology:Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ... million from Merz Pharmaceuticals GmbH (Merz) for ... Memantine for the treatment of,moderate-to-severe Alzheimer,s disease ... an exclusive marketing agreement, NTI currently receives,quarterly ...
... CITY, April 30 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... company focused on,endocrine therapy and oncology, today announced ... CEO of Andros Men,s Health Institutes,in The Netherlands, ... a Poster,Session at the 23rd Annual European Association ...
... ... First Non-GAAP Profit; Sales Guidance Revised Upward, ... Neurology and Cancer, First Quarter 2008 Financial Highlights:, - Soliris(R) (eculizumab) net product sales were ... Q4 2007., - Q1 GAAP net loss was $4.2 million, or $0.11 net loss per share, ...
Cached Biology Technology:AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 2AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 3AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 4AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 5AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 6Alexion Reports First Quarter 2008 Results 2Alexion Reports First Quarter 2008 Results 3Alexion Reports First Quarter 2008 Results 4Alexion Reports First Quarter 2008 Results 5Alexion Reports First Quarter 2008 Results 6Alexion Reports First Quarter 2008 Results 7Alexion Reports First Quarter 2008 Results 8Alexion Reports First Quarter 2008 Results 9Alexion Reports First Quarter 2008 Results 10Alexion Reports First Quarter 2008 Results 11Alexion Reports First Quarter 2008 Results 12
(Date:7/30/2014)... journal Scientific Reports , published by Nature ... that while global temperature is indeed increasing, so too ... each year,s average hottest and coldest temperatures will likely ... a wider range of potential high and low temperate ... even as overall temperatures rise, we may still continue ...
(Date:7/29/2014)... methods and applications for imaging and manipulation of the ... were the inspiration behind Neurophotonics , a new ... optics and photonics. , The first issue coincides with ... States, and a special section features articles that lay ... impact that optics and photonics will have on advancing ...
(Date:7/29/2014)... In the high-tech world of science, researchers sometimes ... Barbara,s Douglas McCauley did just that to study ... muricatum ) on coral reef ecosystems at two ... Using direct observation, animal tracking and computer simulation, ... Ecology, Evolution and Marine Biology, and his colleagues ...
Breaking Biology News(10 mins):Big data confirms climate extremes are here to stay 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3Underwater elephants 2Underwater elephants 3
... 2013)In a series of papers to be presented next ... mechanism operating in the roots of a tropical grass ... greenhouse gas emissions. Referred to as "biological nitrification ... of nitrogen applied to soil as fertilizer into nitrous ...
... This news release is available in German ... daughter; like father, like son. Evolutionary biologists at the universities in ... also applies to inheriting a long life at least for ... descendants of these insects mostly inherit their lifespan from their own ...
... disease indicate future joint problems? Although researchers and clinicians ... chronic inflammatory diseases - periodontal disease and rheumatoid arthritis ... In an article published today in PLOS Pathogens ... and Systemic Diseases group researcher Jan Potempa, PhD, DSc, ...
Cached Biology News:'Grassroots action' in livestock feeding to help curb global climate change 2'Grassroots action' in livestock feeding to help curb global climate change 3'Grassroots action' in livestock feeding to help curb global climate change 4Inheritance of lifespan is sex-dependent in fruit flies 2Bacteria responsible for gum disease facilitates rheumatoid arthritis 2
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Presenilin 2 Immunogen: Synthetic peptide corresponding to residues 31-47 of human Presenilin 2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
SHP-2 Antibody...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
Biology Products: